CYPOLITE SYP
Each 5ml Contains: Cyproheptadine Hydrochloride IP 2mg Tricholine Citrate (65%) IP 275mg In a Flavoured Syrup Base q.s.
| Composition | Each 5ml Contains: Cyproheptadine Hydrochloride IP 2mg Tricholine Citrate (65%) IP 275mg In a Flavoured Syrup Base q.s. |
| Packing | BRUTE AMBER BOTTLE WITH CARTONBRUTE AMBER BOTTLE N - 100 ML |
| MRP | ₹85 |
Product Overview
CYPOLITE SYP is a dual-action therapeutic syrup formulated to counter severe weight loss and poor dietary intake. By stimulating appetite pathways and protecting metabolic health, it ensures predictable therapeutic outcomes for patients experiencing persistent undernutrition. It provides pharma distributors with a high-demand, specialized option within the digestive health segment.
Indications
CYPOLITE SYP is indicated for:
- Persistent Loss of Appetite: Addressing unexplained or stress-induced drops in daily caloric intake.
- Underweight Conditions: Adjunctive management for adults and pediatric patients failing to achieve target body mass indexes.
- Convalescent Support: Restoring nutritional profiles in individuals recovering from major infections, anti-tubercular, or antiretroviral therapies.
- Hepatic Sluggishness: Supporting digestion where diminished appetite coexists with mild liver congestion.
Dosage & Administration
Adults: 10 ml taken two to three times daily, administered 30 minutes prior to meals.
Children (Aged 2 to 14 years): 5 ml taken two to three times daily before meals, adjusted according to response and clinical parameters.
Adverse Effects
Frequently observed physiological responses include:
- Drowsiness or central sedation
- Xerostomia (dry mouth)
- Increased appetite and weight gain changes
- Gastrointestinal symptoms like transient constipation or nausea
View Complete Medical Information
Contraindications
Not suitable for individuals with a history of hypersensitivity to its active molecules. Absolute contraindications include narrow-angle glaucoma, acute asthma attacks, urinary retention, pyloroduodenal obstruction, and treatment regimens involving MAO inhibitors.
Warnings & Precautions
Patients should remain cautious regarding activities requiring high coordination or alertness, such as driving, due to potential sedating effects. Exercise clinical surveillance when prescribing to individuals with elevated intraocular pressure, ischemic heart disease, or renal vulnerability.
Drug Interactions
Synergistic depressant effects occur when combined with alcohol, barbiturates, or anxiolytics. Anticholinergic medications may become potentiated, raising risks of dry mouth or urinary tracking delays.
Storage Instructions
Store in a cool, dark place away from direct light exposure. Do not freeze. Keep safely out of reach of children.
Product image not available
Request This Product
- WHO-GMP Certified Formulations
- Monopoly Rights Available
- Get bulk pricing & MOQ
+91 9689237122 · replies within hours
Interested in this product?
Contact our team to discuss PCD franchise, bulk orders, or contract manufacturing for your market.

